Page 56 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $1.41
52wk Low $0.71 ZYUS Life Sciences Corpora ZYUS $0.97
Unit 204
Saskatoon, SK S7N 4L8

(USD - in millions) www.zyus.com
Market Cap 68.7
Enterprise 70.5
Basic Shares Out. 70.85 COMPANY OVERVIEW
Float 30.54
Institutional Holdings 0.23% Detailed Analysis:Channelchek.com
Short Interest N/A ZYUS is a publicly traded Canadian-based life sciences company
Avg. 90-Day Volume 0.01 focused on the global development and commercialization of regulated
cannabinoid-based pharmaceutical drug product candidates. Through
clinical research, ZYUS is committed to furthering the understanding of
cannabinoids with the clinical development of its pharmaceutical drug
EPS Data product candidates and intellectual property activities to protect its
novel formulations. Additionally, ZYUS is dedicated to delivering high
2021 2022 2023 quality, cGMP/EU GMP-compliant cannabinoid products to patients
CQ1 N/A N/A N/A through the exempt global medical market. The ZYUS vision is to
CQ2 N/A N/A (0.28) reimagine the potential of pain therapeutics by pursuing regulatory
approval of cannabinoid formulations and elevating cannabinoids as a
CQ3 N/A N/A (0.06) standard of care in pursuit of transformational impact on patients’ lives.
CQ4 N/A N/A (0.07)
CY N/A N/A (0.46) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.67
ROE (ttm) -83.53
Debt-to-Total Cap. (mrq) 18.86
Fiscal Year End 31-Dec
Unit 204 Saskatoon SK S7N 4L8

Key Executives
CEO: Zettl, Brent
CFO: Hyshka, John
COO: N/A
IR: Miller, Tim
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures